TMTyler Maser

Tyler Maser

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tyler Maser has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Giselle Saulnier Sholler

    Penn State University, College of Medicine, Hershey, PA

    2 shared publications
  • Jeffrey Bond

    Pediatric Oncology Translational Research Program Helen DeVos Children’s Hospital Grand Rapids MI USA

    2 shared publications
  • Abhinav B. Nagulapally

    Pediatric Oncology Translational Research Program, Helen DeVos Children's Hospital, Grand Rapids, Michigan

    1 shared publication
  • Abhinav Nagulapally

    Pediatric Oncology Translational Research Program Helen DeVos Children’s Hospital Grand Rapids MI USA

    1 shared publication
  • Anna Ostrander

    Pediatric Oncology Translational Research Program Helen DeVos Children’s Hospital Grand Rapids MI USA

    1 shared publication
  • Austin Goodyke

    Pediatric Oncology Translational Research Program Helen DeVos Children’s Hospital Grand Rapids MI USA

    1 shared publication

Latest Publications

  • Open Access

    The MDM2 inhibitor CGM097 combined with the BET inhibitor OTX015 induces cell death and inhibits tumor growth in models of neuroblastoma

    by Tyler Maser, Joseph Zagorski, Shannon Kelly, Anna Ostrander, Austin Goodyke, Abhinav Nagulapally, Jeffrey Bond, Yeonhee Park, Giselle Saulnier Sholler

    Background: Neuroblastoma (NB) is the most common extracranial solid tumor in infants and children, with amplification of the oncogene MYCN being a hallmark of high‐risk disease and poor prognosis. Although less frequent, overexpression of MYC is similarly an indicator of poor prognosis. Most NB tumors initially respond to chemotherapy, however, most will relapse, resulting in chemoresistant disease. After relapse, there is growing evidence of p53 inactivation. MYC/MYCN and MDM2 have been shown to interact and contribute to NB growth and disease progression. MDM2 inhibitors and Bromodomain and Extra‐Terminal domain (BET) inhibitors have both shown promise in treating NB by increasing the expression of p53 and decreasing MYC/MYCN expression, respectively. Our study focuses on the combined treatment of a MDM2 inhibitor (CGM097) with a BET inhibitor (OTX015) in neuroblastoma.Methods: Two p53 wild‐type and two p53 mutant established neuroblastoma cells lines were used to test this combination. Ray design assays were used to test whether this combination was synergistically cytotoxic to NB cells. Western blots were performed to check signaling pathways of interest after drug treatment. IncuCyte imaging and flow cytometry were utilized to quantify the apoptotic and cytostatic effects of these drugs on NB cells. In vivo studies were carried out to test the antitumor effect of this combination in a living host.Results: The combination of CGM097 and OTX015 resulted in p53 activation, decreased expression of MYC family proteins and a subsequent synergistic increase in NB cell death.Conclusion: This study warrants further investigation into the combination of MDM2 inhibitors and BET inhibitors for the treatment in NB.


  • Open Access

    Tolcapone induces oxidative stress leading to apoptosis and inhibition of tumor growth in Neuroblastoma

    by Tyler Maser, Maria Rich, David Hayes, Ping Zhao, Abhinav B. Nagulapally, Jeffrey Bond, Giselle Saulnier Sholler

    Catechol‐O‐methyltransferase (COMT) is an enzyme that inactivates dopamine and other catecholamines by O‐methylation. Tolcapone, a drug commonly used in the treatment of Parkinson's disease, is a potent inhibitor of COMT and previous studies indicate that Tolcapone increases the bioavailability of dopamine in cells. In this study, we demonstrate that Tolcapone kills neuroblastoma (NB) cells in preclinical models by inhibition of COMT. Treating four established NB cells lines (SMS‐KCNR, SH‐SY5Y, BE(2)‐C, CHLA‐90) and two primary NB cell lines with Tolcapone for 48 h decreased cell viability in a dose‐dependent manner, with IncuCyte imaging and Western blotting indicating that cell death was due to caspase‐3‐mediated apoptosis. Tolcapone also increased ROS while simultaneously decreasing ATP‐per‐cell in NB cells. Additionally, COMT was inhibited by siRNA in NB cells and showed similar increases in apoptotic markers compared to Tolcapone. In vivo xenograft models displayed inhibition of tumor growth and a significant decrease in time‐to‐event in mice treated with Tolcapone compared to untreated mice. These results indicate that Tolcapone is cytotoxic to neuroblastoma cells and invite further studies into Tolcapone as a promising novel therapy for the treatment of neuroblastoma.